Immix Biopharma, Inc. (IMMX)

NASDAQ: IMMX · IEX Real-Time Price · USD
4.03 -0.20 (-4.73%)
Jan 25, 2022 9:50 AM EST - Market open
Market Cap30.53M
Revenue (ttm)n/a
Net Income (ttm)-2.11M
Shares Out7.57M
EPS (ttm)-0.28
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume96,415
Open4.04
Previous Close4.23
Day's Range3.92 - 4.19
52-Week Range2.85 - 8.68
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About IMMX

Immix Biopharma is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics (“TSTx”)™ in oncology and inflammation. Our lead asset, IMX-110, is currently in Phase 1b/2a clinical trials for solid tumors in the United States and Australia. IMX-110 is a negatively-charged TSTx that simultaneously disables resistance pathways with a poly-kinase inhibitor, and induces tumor cell death leveraging our TME Normalization™ Technology, delivered deep into the tumor micro-environment (“TME”). Our propr...

IndustryBiotechnology
IPO DateDec 16, 2021
CEOIlya Rachman, MD PhD
Employees2
Stock ExchangeNASDAQ
Ticker SymbolIMMX
Full Company Profile

Financial Performance

Financial Statements

News

ImmixBio Announces Positive IMX-110 Phase 1b/2a Interim Clinical Trial Safety Data Demonstrating 100% Completion of P...

A chart accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b83a7ede-262b-4777-a2f9-beb13ee761bc

6 days ago - GlobeNewsWire

Check These 3 Penny Stocks Out For Your Morning Watchlist

Here are three penny stocks to add to your watchlist right now The post Check These 3 Penny Stocks Out For Your Morning Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | Pen...

Other symbols:BJDXOCGN
1 week ago - PennyStocks

ImmixBio IMX-110 Produced 50% Positive Response Rate in First-Line-Therapy-Resistant Cancer, Surpassing the Standard ...

A graph accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/14a74b9a-30ad-4410-a0d6-9a084753dd4c

1 week ago - GlobeNewsWire

Immix Biopharma Announces IMMX Investors Day to be Held on February 1, 2022 + Q&A Platform for All Shareholders

Los Angeles, CA, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company pioneering Tissue Specific Therapeutics (TSTx)TM target...

2 weeks ago - GlobeNewsWire

Why Immix Biopharma Shares Are Rising Today

Immix Biopharma Inc (NASDAQ: IMMX) is trading higher Tuesday on continued momentum after the U.S. Food and Drug Administration granted Rare Pediatric Disease designation for IMX-110 for the treatment of...

3 weeks ago - Benzinga

Best Biotech Penny Stocks to Buy Now? 3 to Watch in January

Check these three biotech penny stocks out for your watchlist right now The post Best Biotech Penny Stocks to Buy Now? 3 to Watch in January appeared first on Penny Stocks to Buy, Picks, News and Inform...

Other symbols:HOTHPSTV
3 weeks ago - PennyStocks

IMMX Stock Alert: The Massive FDA Win That Has Immix Biopharma Blasting Higher Today

Immix Biopharma (IMMX) stock is taking off Monday thanks to a Rare Pediatric Disease designation from the U.S. Food and Drug Administration. The post IMMX Stock Alert: The Massive FDA Win That Has Immix...

3 weeks ago - InvestorPlace

Best Penny Stocks to Buy Today? 3 For Your Watchlist in January

Are these penny stocks on your watchlist right now? The post Best Penny Stocks to Buy Today?

Other symbols:CELZPTE
3 weeks ago - PennyStocks

Immix Shares Rally On FDA Rare Pediatric Disease Tag For Cancer Program In Children

The FDA has granted Rare Pediatric Disease (RPD) designation to newly listed Immix Biopharma Inc's (NASDAQ: IMMX) IMX-110 for rhabdomyosarcoma, a form of pediatric cancer. IMX-110 is currently being eva...

3 weeks ago - Benzinga

Immix Biopharma's stock rockets after pediatric cancer treatment granted RPD by the FDA

Shares of Immix Biopharma Inc. IMMX, +9.20% rocketed 66.0% in premarket trading Monday, after the biopharmaceutical company said its IMX-110 was granted Rare Pediatric Disease (RPD) designation by the F...

3 weeks ago - Market Watch

U.S. Food and Drug Administration Approves Immix Biopharma Rare Pediatric Disease Designation for IMX-110 as a Treatm...

LOS ANGELES, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)TM targeting ...

3 weeks ago - GlobeNewsWire

Immix Biopharma, Inc. Announces Closing of Initial Public Offering

LOS ANGELES, CA, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company pioneering Tissue Specific Therapeutics (TSTx)TM target...

1 month ago - GlobeNewsWire

Immix Biopharma, Inc. Announces Pricing of Initial Public Offering

LOS ANGELES, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company pioneering Tissue Specific Therapeutics (TSTx)TM targeting ...

1 month ago - GlobeNewsWire